In the often-volatile world of biotech stocks, shares of small-cap Blueprint Medicines (NASDAQ: BPMC) have proven surprisingly steady over the past 12 months. But the stock could be gearing up for a bull run. That's thanks to an expanded set of prescription guidelines approved recently for the company's biggest-earning drug, Ayvakit.

But Blueprint is still burning far more money than it brings in, and that is unlikely to change in the near term. So should you think about buying this stock, or are its warts too much to bear? Let's take a look.

Ayvakit treats indolent systemic mastocytosis (ISM), a rare and often debilitating blood disorder that causes organ damage as well as fatigue, not to mention a slew of other symptoms which are often unpredictable both in terms of their severity and their duration.

Continue reading

Source Fool.com